NEWTOWN, Pa.--(BUSINESS WIRE)--CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that the U.S. Patent and Trademark Office (USPTO) has informed the Company that its patent application No. 11/061,866, covering Oracea(R), will issue on June 19, 2007 as Patent No. 7,232,572 (the “572 Patent”). This patent covers the use of tetracyclines in a sub-antibiotic amount, including Oracea, specifically for the treatment of papules and pustules associated with rosacea. The USPTO issued a notice of allowance of this application in February 2007. CollaGenex received FDA approval for Oracea in May 2006 and is currently marketing Oracea to the U.S. dermatology community.
